A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Trial Profile

A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Nov 2017 This trial has been completed in Austria.
    • 12 Sep 2017 Results (data cut off: 4 March, 2014) predicting survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments, presented at the 42nd European Society for Medical Oncology Congress.
    • 06 Jun 2017 Results assessing correlation between pretreatment liver metastases and survival in durvalumab treated non-small cell lung cancer patients in two independent clinical trials (CP1108/NCT01693562 and ATLANTIC/NCT02087423), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top